9 mg 玛兹杜肽用于中国肥胖成人减重的 GLORY-2 随机临床试验
GLORY-2 是一项在中国 27 家医院开展的双盲、安慰剂对照 3 期随机试验,纳入 BMI≥30 的中国肥胖成人,按 2:1 随机接受每周一次 9 mg 玛兹杜肽皮下注射或安慰剂治疗 60 周。结果显示玛兹杜肽组体重平均下降 16.65%,84.3% 的参与者体重下降≥5%,均显著优于安慰剂,但胃肠道不良事件更常见。
要点
- 9 mg 玛兹杜肽每周一次治疗 60 周,平均体重降幅达 16.65%。
- 84.3% 的玛兹杜肽组参与者体重下降≥5%,安慰剂组为 33.1%。
- 呕吐、恶心和腹泻是最常见不良事件,多为轻至中度。
核心结论
- 与安慰剂相比,9 mg 玛兹杜肽可为中国中重度肥胖成人带来有临床意义的体重下降,但胃肠道不良反应更常见。
研究设计与样本
- 纳入伴或不伴 2 型糖尿病的中国肥胖成人(BMI≥30),按 2:1 随机接受每周一次 9 mg 玛兹杜肽皮下注射(n=308)或安慰剂(n=154),疗程 60 周,辅以低热量饮食和增加体力活动。
- 共 461 名参与者接受至少 1 剂研究治疗并纳入疗效和安全性分析(玛兹杜肽组 307 例,安慰剂组 154 例)。
主要发现
- 第 60 周时,玛兹杜肽组体重较基线平均变化百分比为 -16.65%(95%CI,-18.19% 至 -15.12%),安慰剂组为 -1.50%(95%CI,-3.43% 至 0.43%),组间差异 -15.15%(95%CI,-17.22% 至 -13.09%;P < .001)。
- 第 60 周时,玛兹杜肽组 84.3% 的参与者体重下降≥5%,安慰剂组为 33.1%,组间差异 51.6%(95%CI,43.0% 至 60.1%;P < .001)。
- 导致研究治疗终止的不良事件发生率在玛兹杜肽组为 2.9%,安慰剂组为 0%。
- 最常见不良事件为呕吐(玛兹杜肽组 53.1% vs 安慰剂组 1.3%)、恶心(46.9% vs 3.2%)和腹泻(39.4% vs 6.5%),大多数不良事件为轻至中度。
临床怎么用
- 对于中国中重度肥胖成人,可考虑每周一次 9 mg 玛兹杜肽作为减重治疗选择,需配合饮食控制和运动。
- 用药期间应关注呕吐、恶心、腹泻等胃肠道不良反应,多数为轻至中度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Obesity is a worldwide problem and a major public health issue in China. OBJECTIVE: To evaluate the efficacy and safety of mazdutide (a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist) in Chinese adults with obesity (defined as a body mass index of ≥30). DESIGN, SETTING, AND PARTICIPANTS: A double-blind, placebo-controlled, phase 3, randomized clinical trial including Chinese adults with or without type 2 diabetes that was conducted at 27 hospitals from December 2023 to November 2025. INTERVENTIONS: Participants were randomized in a 2:1 ratio to receive a once weekly, 9-mg dose of mazdutide administered subcutaneously (n = 308) or placebo (n = 154) as an adjunct to a reduced calorie diet and increased physical activity for 60 weeks. MAIN OUTCOMES AND MEASURES: The coprimary outcomes were the percentage change in body weight from baseline and a weight reduction of at least 5% at week 60. The efficacy and safety analyses were performed in participants who received at least 1 dose of the study treatment. RESULTS: A total of 461 participants (295 [64.0%] female; 16.1% with type 2 diabetes; mean age, 33.9 [SD, 8.4] years; body weight, 94.0 [SD, 13.8] kg; BMI, 34.3 [SD, 3.2]) received the study treatment (307 in the mazdutide group and 154 in the placebo group) and were included in the analyses. At week 60, the mean percentage change in body weight from baseline was -16.65% (95% CI, -18.19% to -15.12%) in the mazdutide group compared with -1.50% (95% CI, -3.43% to 0.43%) in the placebo group (between-group difference, -15.15% [95% CI, -17.22% to -13.09%]; P < .001). At week 60, 84.3% of participants in the mazdutide group had a body weight reduction of 5% or greater compared with 33.1% in the placebo group (between-group difference, 51.6% [95% CI, 43.0% to 60.1%]; P < .001). Adverse events leading to study treatment discontinuation were reported in 2.9% of participants in the mazdutide group compared with 0% in the placebo group. The most common adverse events were vomiting (53.1% in the mazdutide group vs 1.3% in the placebo group), nausea (46.9% vs 3.2%, respectively), and diarrhea (39.4% vs 6.5%); most of the adverse events were mild to moderate in severity. CONCLUSIONS AND RELEVANCE: Mazdutide provided clinically meaningful weight reduction in Chinese adults with moderate to severe obesity compared with placebo, but participants receiving the drug experienced gastrointestinal adverse reactions compared with those receiving placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06164873.
引用
- Gao L, Jiang H, Cai H, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026. PMID: 42251595. doi:10.1001/jama.2026.8142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。